$TBPH
Theravance Biopharma Inc

2020 Q4 Form 10-Q Financial Statement

#000155837020013233 Filed on November 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $18.73M $18.26M $12.43M
YoY Change -36.51% 46.91% -3.2%
Cost Of Revenue $0.00 $0.00
YoY Change -100.0%
Gross Profit $18.70M $12.40M
YoY Change -36.61% 2.48%
Gross Profit Margin 99.84% 99.78%
Selling, General & Admin $30.10M $27.50M $25.62M
YoY Change -8.79% 7.33% 17.05%
% of Gross Profit 160.96% 206.63%
Research & Development $65.20M $67.37M $52.01M
YoY Change -3.55% 29.54% -1.3%
% of Gross Profit 348.66% 419.4%
Depreciation & Amortization $1.410M $1.360M $1.810M
YoY Change -19.89% -24.86% 191.94%
% of Gross Profit 7.54% 14.6%
Operating Expenses $95.22M $94.87M $77.63M
YoY Change -4.85% 22.21% 3.11%
Operating Profit -$76.49M -$76.62M -$65.20M
YoY Change 8.39% 17.51% 4.41%
Interest Expense $9.300M $11.57M $8.068M
YoY Change 86.0% 43.44% 277.54%
% of Operating Profit
Other Income/Expense, Net $0.00 $1.235M $2.089M
YoY Change -40.88% 51.82%
Pretax Income -$67.20M -$73.55M -$63.98M
YoY Change 2.44% 14.95% 6.48%
Income Tax -$8.800M $93.00K -$5.552M
% Of Pretax Income
Net Earnings -$58.43M -$73.64M -$58.43M
YoY Change -10.93% 26.03% -1.69%
Net Earnings / Revenue -311.98% -403.37% -470.19%
Basic Earnings Per Share -$0.92 -$1.16
Diluted Earnings Per Share -$0.92 -$1.16 -$1.045M
COMMON SHARES
Basic Shares Outstanding 63.98M 63.30M 56.69M
Diluted Shares Outstanding 63.30M 55.86M

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $292.9M $358.3M $319.7M
YoY Change 4.31% 12.1% 6.42%
Cash & Equivalents $81.47M $93.28M $102.4M
Short-Term Investments $211.5M $265.1M $217.3M
Other Short-Term Assets $30.70M $31.10M $14.60M
YoY Change 332.39% 113.01% 100.0%
Inventory
Prepaid Expenses
Receivables $15.90M $12.40M $87.00K
Other Receivables $53.80M $48.90M $16.60M
Total Short-Term Assets $393.3M $450.7M $355.7M
YoY Change 16.21% 26.73% 6.93%
LONG-TERM ASSETS
Property, Plant & Equipment $16.42M $15.43M $12.19M
YoY Change 29.88% 26.59% -1.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $12.75M $0.00 $24.90M
YoY Change 155.0% -100.0% 23.27%
Other Assets $2.451M $810.0K $1.305M
YoY Change 54.15% -37.93% -49.81%
Total Long-Term Assets $75.72M $61.46M $89.69M
YoY Change 7.65% -31.47% 133.55%
TOTAL ASSETS
Total Short-Term Assets $393.3M $450.7M $355.7M
Total Long-Term Assets $75.72M $61.46M $89.69M
Total Assets $469.1M $512.2M $445.3M
YoY Change 14.73% 15.01% 20.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.775M $6.442M $8.713M
YoY Change 42.39% -26.06% 135.49%
Accrued Expenses $85.90M $79.60M $57.70M
YoY Change 31.15% 37.95% 40.73%
Deferred Revenue $11.52M $18.20M $33.75M
YoY Change -63.51% -46.06%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $19.30M $0.00 $8.700M
YoY Change 94.95% -100.0%
Total Short-Term Liabilities $123.6M $104.3M $108.8M
YoY Change 10.62% -4.18% 6.69%
LONG-TERM LIABILITIES
Long-Term Debt $599.8M $611.2M $447.6M
YoY Change 34.73% 36.55% 99.29%
Other Long-Term Liabilities $1.833M $9.704M $8.900M
YoY Change -91.39% 9.03% -84.6%
Total Long-Term Liabilities $1.833M $9.704M $8.900M
YoY Change -91.39% 9.03% -96.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $123.6M $104.3M $108.8M
Total Long-Term Liabilities $1.833M $9.704M $8.900M
Total Liabilities $125.4M $114.0M $117.7M
YoY Change -5.7% -3.18% -69.37%
SHAREHOLDERS EQUITY
Retained Earnings -$1.527B -$1.468B -$1.183B
YoY Change 22.27% 24.11%
Common Stock $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$303.8M -$261.5M -$182.8M
YoY Change
Total Liabilities & Shareholders Equity $469.1M $512.2M $445.3M
YoY Change 14.73% 15.01% 20.04%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$58.43M -$73.64M -$58.43M
YoY Change -10.93% 26.03% -1.69%
Depreciation, Depletion And Amortization $1.410M $1.360M $1.810M
YoY Change -19.89% -24.86% 191.94%
Cash From Operating Activities -$64.92M -$77.03M -$44.63M
YoY Change 0.89% 72.6% -8.88%
INVESTING ACTIVITIES
Capital Expenditures -$1.250M -$2.050M -$70.00K
YoY Change -4.58% 2828.57% -96.26%
Acquisitions
YoY Change
Other Investing Activities $53.62M $68.58M -$23.58M
YoY Change 249.09% -390.84% -148.59%
Cash From Investing Activities $52.37M $66.54M -$23.65M
YoY Change 272.48% -381.35% -150.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 750.0K -970.0K -130.0K
YoY Change -148.39% 646.15% -59.37%
NET CHANGE
Cash From Operating Activities -64.92M -77.03M -44.63M
Cash From Investing Activities 52.37M 66.54M -23.65M
Cash From Financing Activities 750.0K -970.0K -130.0K
Net Change In Cash -11.80M -11.46M -68.41M
YoY Change -77.24% -83.25% 2481.51%
FREE CASH FLOW
Cash From Operating Activities -$64.92M -$77.03M -$44.63M
Capital Expenditures -$1.250M -$2.050M -$70.00K
Free Cash Flow -$63.67M -$74.98M -$44.56M
YoY Change 1.0% 68.27% -5.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Central Index Key
EntityCentralIndexKey
0001583107
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57015000
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63956000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36033
dei Entity Registrant Name
EntityRegistrantName
THERAVANCE BIOPHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
KY
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1226628
dei Entity Address Address Line1
EntityAddressAddressLine1
PO Box 309
dei Entity Address Address Line2
EntityAddressAddressLine2
Ugland House, South Church Street
dei Entity Address City Or Town
EntityAddressCityOrTown
George Town, Grand Cayman
dei Entity Address Country
EntityAddressCountry
KY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
KY1-1104
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
808-6000
dei Security12b Title
Security12bTitle
Ordinary Share $0.00001 Par Value
dei Trading Symbol
TradingSymbol
TBPH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
63981317
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93282000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58064000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
265065000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
222767000
CY2020Q3 tbph Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
12399000
CY2019Q4 tbph Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
11996000
CY2019Q4 tbph Receivables From Licensing Arrangements
ReceivablesFromLicensingArrangements
10000000
CY2020Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
48909000
CY2019Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
28574000
CY2020Q3 tbph Prepaid Clinical And Development Services
PrepaidClinicalAndDevelopmentServices
20761000
CY2019Q4 tbph Prepaid Clinical And Development Services
PrepaidClinicalAndDevelopmentServices
2736000
CY2020Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
10308000
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
4351000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
450724000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
338488000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15430000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12644000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
4985000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44391000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
46604000
CY2019Q4 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
3682000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
833000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
833000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
810000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1590000
CY2020Q3 us-gaap Assets
Assets
512188000
CY2019Q4 us-gaap Assets
Assets
408826000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6442000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4758000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
30472000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
28180000
CY2020Q3 tbph Accrued Clinical And Development Expenses Current
AccruedClinicalAndDevelopmentExpensesCurrent
26944000
CY2019Q4 tbph Accrued Clinical And Development Expenses Current
AccruedClinicalAndDevelopmentExpensesCurrent
17587000
CY2020Q3 us-gaap Interest Payable Current
InterestPayableCurrent
5791000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
5659000
CY2019Q4 tbph Non Recourse Debt Current
NonRecourseDebtCurrent
9851000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9685000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7762000
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
18204000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
31575000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6732000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6331000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
104270000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
111703000
CY2020Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
226695000
CY2019Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
225890000
CY2020Q3 tbph Non Recourse Debt Due2035 Noncurrent
NonRecourseDebtDue2035Noncurrent
384482000
CY2019Q4 tbph Non Recourse Debt Noncurrent
NonRecourseDebtNoncurrent
219300000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47823000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47725000
CY2020Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
750000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
6761000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9704000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21287000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63956000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57015000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1206524000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1024614000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
122000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
145000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1468183000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1248600000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-261536000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-223840000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
512188000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
408826000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18257000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12427000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
53127000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
43915000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
67371000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52006000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
195788000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
152223000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
27501000
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
25622000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
78606000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
73035000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
94872000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
77628000
us-gaap Operating Expenses
OperatingExpenses
274394000
us-gaap Operating Expenses
OperatingExpenses
225258000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-76615000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-65201000
us-gaap Operating Income Loss
OperatingIncomeLoss
-221267000
us-gaap Operating Income Loss
OperatingIncomeLoss
-181343000
CY2020Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
13403000
CY2019Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
7197000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-15464000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1235000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2089000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2033000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7258000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-73550000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
48299000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
21792000
CY2020Q3 us-gaap Interest Expense
InterestExpense
11573000
CY2019Q3 us-gaap Interest Expense
InterestExpense
8068000
us-gaap Interest Expense
InterestExpense
32905000
us-gaap Interest Expense
InterestExpense
23827000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-63983000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-219304000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-176120000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
93000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5552000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
279000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5271000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-73643000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-58431000
us-gaap Net Income Loss
NetIncomeLoss
-219583000
us-gaap Net Income Loss
NetIncomeLoss
-170849000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-158000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-35000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-23000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
260000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-73801000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58466000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-219606000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-170589000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.16
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.05
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.55
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.08
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
63303000
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55858000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
61881000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55445000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15564000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13019000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
47425000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
36538000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-202336000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15564000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000
CY2020Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
987000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-158000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-73643000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-261536000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-223840000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
139915000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2545000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
47425000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
960000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
8935000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-23000
us-gaap Net Income Loss
NetIncomeLoss
-219583000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-261536000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-137224000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13019000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
428000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
36538000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2973000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2743000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
260000
us-gaap Net Income Loss
NetIncomeLoss
-170849000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-182805000
us-gaap Net Income Loss
NetIncomeLoss
-219583000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-534000
tbph Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-9597000
CY2019Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
562000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-35000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-58431000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-182805000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-51589000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2605000
us-gaap Net Income Loss
NetIncomeLoss
-170849000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
5394000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
4676000
tbph Amortization And Accretion Income
AmortizationAndAccretionIncome
1023000
tbph Amortization And Accretion Income
AmortizationAndAccretionIncome
2599000
us-gaap Share Based Compensation
ShareBasedCompensation
47425000
us-gaap Share Based Compensation
ShareBasedCompensation
36538000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2213000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
3029000
tbph Equity Method Investments Undistributed Earnings
EquityMethodInvestmentsUndistributedEarnings
20337000
tbph Equity Method Investments Undistributed Earnings
EquityMethodInvestmentsUndistributedEarnings
11239000
tbph Interest Shortfall On2035 Notes
InterestShortfallOn2035Notes
10144000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-15464000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
42000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-148000
tbph Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-5458000
tbph Increase Decrease In Prepaid Clinical And Development Services
IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices
18025000
tbph Increase Decrease In Prepaid Clinical And Development Services
IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices
575000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
2274000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
106000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-37000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
3700000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-541000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2133000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-543000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-178000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-9846000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
132000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
4482000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-19382000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-21661000
tbph Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
2021000
tbph Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2307000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
265000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2835000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
35218000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-268122000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58897000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-5288000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-185478000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-173845000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
5372000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1873000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
337556000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
366412000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
281318000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
266168000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
19928000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
35000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
5000
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
5000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41647000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-97112000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
139915000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
380000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
5326000
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
11470000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
235347000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2545000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2605000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
960000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2973000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
8935000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2743000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
262342000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
378854000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94115000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
110732000
us-gaap Interest Paid Net
InterestPaidNet
20287000
us-gaap Interest Paid Net
InterestPaidNet
17097000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
14000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
22000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
49847000
tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
3412000
CY2019Q3 tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-832000
tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-480000
tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-863000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63303000
CY2020Q3 tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-414000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>Furthermore, the estimates used in the preparation of the Company’s condensed consolidated financial statements may change due to the uncertainty and disruption in the global economy and financial markets related to the novel coronavirus (“COVID-19”) pandemic. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenue, expenses, clinical trials, and research and development costs, will depend on future developments that are highly uncertain and may be impacted by the emergence of new information concerning the COVID-19 pandemic and the actions taken to contain or treat the disease.</p>
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-73643000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-58431000
us-gaap Net Income Loss
NetIncomeLoss
-219583000
us-gaap Net Income Loss
NetIncomeLoss
-170849000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63717000
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56690000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62361000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56308000
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55858000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61881000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55445000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.16
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.05
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.55
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.08
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14739000
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14016000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13242000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13167000
tbph Profit Loss Percentage As Per Collaboration Agreement
ProfitLossPercentageAsPerCollaborationAgreement
0.35
CY2020Q3 tbph Collaborative Arrangements Revenue
CollaborativeArrangementsRevenue
7261000
CY2019Q3 tbph Collaborative Arrangements Revenue
CollaborativeArrangementsRevenue
8836000
tbph Collaborative Arrangements Revenue
CollaborativeArrangementsRevenue
19381000
tbph Collaborative Arrangements Revenue
CollaborativeArrangementsRevenue
21661000
CY2018Q1 tbph Profit Loss Percentage As Per Collaboration Agreement
ProfitLossPercentageAsPerCollaborationAgreement
0.33
CY2020Q3 tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
1404000
CY2019Q3 tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
983000
tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
5796000
CY2020Q3 tbph Percentage Of Note To Be Retained
PercentageOfNoteToBeRetained
0.05
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93282000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102403000
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
833000
CY2019Q3 us-gaap Restricted Cash
RestrictedCash
8329000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94115000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
110732000
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
307553000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
126000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
307678000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
274014000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
148000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
274159000
tbph Marketable Securities Maximum Contractual Maturity Period
MarketableSecuritiesMaximumContractualMaturityPeriod
P11M
tbph Marketable Securities Average Contractual Maturity Period
MarketableSecuritiesAverageContractualMaturityPeriod
P3M
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
15088000
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1000
CY2020Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
15088000
CY2020Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1000
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
33644000
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
3000
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
33644000
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
3000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
19900000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15564000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13019000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
47425000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
36538000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000
CY2020Q3 us-gaap Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries
DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries
0
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5500000
CY2020Q1 us-gaap Share Price
SharePrice
27.00
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
148500000

Files In Submission

Name View Source Status
0001558370-20-013233-index-headers.html Edgar Link pending
0001558370-20-013233-index.html Edgar Link pending
0001558370-20-013233.txt Edgar Link pending
0001558370-20-013233-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tbph-20200930.xsd Edgar Link pending
tbph-20200930x10q.htm Edgar Link pending
tbph-20200930x10q_htm.xml Edgar Link completed
tbph-20200930xex10d1.htm Edgar Link pending
tbph-20200930xex10d1001.jpg Edgar Link pending
tbph-20200930xex31d1.htm Edgar Link pending
tbph-20200930xex31d2.htm Edgar Link pending
tbph-20200930xex32d1.htm Edgar Link pending
tbph-20200930_cal.xml Edgar Link unprocessable
tbph-20200930_def.xml Edgar Link unprocessable
tbph-20200930_lab.xml Edgar Link unprocessable
tbph-20200930_pre.xml Edgar Link unprocessable